Even though the exact underlying mechanism that drives aberrant expression of NFAT5 in tumor tissues remains elusive, the advent of selective COX2 inhibitors as anti-cancer therapies could be a useful tool for EnCa. This evidence concerns the gene PTGS2 and neoplasm.